An Inflection Point in Cancer Protein Biomarkers: What was and What's Next

[1]  David H Perlman,et al.  Initial recommendations for performing, benchmarking and reporting single-cell proteomics experiments , 2022, Nature Methods.

[2]  R. Aebersold,et al.  The 2022 Report on the Human Proteome from the HUPO Human Proteome Project. , 2022, Journal of proteome research.

[3]  H. Scher,et al.  BLOODPAC: Collaborating to chart a path towards blood‐based screening for early cancer detection , 2022, Clinical and translational science.

[4]  Cancer Moonshot aims at liquid biopsies , 2022, Nature Biotechnology.

[5]  R. Gibbs,et al.  Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer , 2022, Cancer discovery.

[6]  Jia Liu,et al.  Clinical applications of mass spectrometry‐based proteomics in cancer: Where are we? , 2022, Proteomics.

[7]  A. Biankin,et al.  ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. , 2022, The Lancet. Oncology.

[8]  A. Barker,et al.  Translating “Big Data” in Oncology for Clinical Benefit: Progress or Paralysis , 2022, Cancer research.

[9]  J. Reis-Filho,et al.  Delivering precision oncology to patients with cancer , 2022, Nature Medicine.

[10]  S. Balasubramanian,et al.  Early detection of cancer , 2022, Science.

[11]  C. Deane,et al.  Challenges and Opportunities for Bayesian Statistics in Proteomics , 2022, Journal of proteome research.

[12]  D. Page.  The Human Tumor Atlas Network’s beginning steps toward the future of collaborative multi-omic discovery , 2022, Cell reports. Medicine.

[13]  Albert J. Vilella,et al.  Hydroxymethylation profile of cell-free DNA is a biomarker for early colorectal cancer , 2021, Scientific Reports.

[14]  S. Shah,et al.  Harnessing multimodal data integration to advance precision oncology , 2021, Nature Reviews Cancer.

[15]  S. Bhatia,et al.  Synthetic biomarkers: a twenty-first century path to early cancer detection , 2021, Nature Reviews Cancer.

[16]  J. Krischer,et al.  Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation , 2021, Nature Protocols.

[17]  Arun Sharma,et al.  Machine Learning Assisted Prediction of Prognostic Biomarkers Associated With COVID-19, Using Clinical and Proteomics Data , 2021, Frontiers in Genetics.

[18]  J. Sturmberg.  Health and Disease Are Dynamic Complex-Adaptive States Implications for Practice and Research , 2021, Frontiers in Psychiatry.

[19]  P. Bankhead,et al.  Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer , 2021, bioRxiv.

[20]  I. Katrukha,et al.  Myocardial Injury and the Release of Troponins I and T in the Blood of Patients. , 2020, Clinical chemistry.

[21]  David S. Wishart,et al.  MarkerDB: an online database of molecular biomarkers , 2020, Nucleic Acids Res..

[22]  A. Guddati,et al.  Clinical endpoints in oncology - a primer. , 2021, American journal of cancer research.

[23]  J. Byrd,et al.  Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial , 2020, Nature Medicine.

[24]  Rebekah L. Gundry,et al.  A high-stringency blueprint of the human proteome , 2020, Nature Communications.

[25]  H. Frieboes,et al.  Multicompartment modeling of protein shedding kinetics during vascularized tumor growth , 2020, Scientific Reports.

[26]  Lisa McShane,et al.  Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group , 2020, Clinical Chemistry.

[27]  R. Bast,et al.  Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women , 2020, Cancers.

[28]  Nancy R. Zhang,et al.  The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution , 2020, Cell.

[29]  D. Ho.  Artificial intelligence in cancer therapy , 2020, Science.

[30]  Leon Xu,et al.  Machine Learning in Mass Spectrometric Analysis of DIA Data , 2020, Proteomics.

[31]  Ash A. Alizadeh,et al.  A mathematical model of ctDNA shedding predicts tumor detection size , 2020, Science Advances.

[32]  H. Moch,et al.  The single-cell pathology landscape of breast cancer , 2020, Nature.

[33]  D. Yee,et al.  I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer , 2019, Current Breast Cancer Reports.

[34]  J. P. Meza-Espinoza,et al.  BCR/ABL1 Transcripts in Healthy Individuals: A Comparative Analysis Between First-Degree Relatives of Patients with Chronic Myelogenous Leukemia and Subjects without Antecedents of the Disease. , 2019, Annals of clinical and laboratory science.

[35]  S. De,et al.  Integrating machine learning and multiscale modeling—perspectives, challenges, and opportunities in the biological, biomedical, and behavioral sciences , 2019, npj Digital Medicine.

[36]  Laura A Cox,et al.  The Need for Multi-Omics Biomarker Signatures in Precision Medicine , 2019, International journal of molecular sciences.

[37]  Motomi Osato,et al.  Systematic Review of Normal Subjects Harbouring BCR-ABL1 Fusion Gene , 2019, Acta Haematologica.

[38]  Frank Klont,et al.  Pre- and Post-analytical Factors in Biomarker Discovery. , 2019, Methods in molecular biology.

[39]  Youngsoo Kim,et al.  Method Validation by CPTAC Guidelines for Multi-protein Marker Assays Using Multiple Reaction Monitoring-mass Spectrometry , 2019, Biotechnology and Bioprocess Engineering.

[40]  Jeffrey R. Whiteaker,et al.  Clinical potential of mass spectrometry-based proteogenomics , 2018, Nature Reviews Clinical Oncology.

[41]  B. Chabner,et al.  Application of Cell-free DNA Analysis to Cancer Treatment. , 2018, The New England journal of medicine.

[42]  G. Guyatt,et al.  Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline , 2018, British Medical Journal.

[43]  P. Fornara,et al.  Innovation in der individualisierten Medizin , 2018, Der Urologe.

[44]  M. Thiagarajan.  Abstract 784: NCI CPTAC phase III, proteogenomic analysis of 10 cancers , 2018, Experimental and Molecular Therapeutics.

[45]  A. Giobbie-Hurder,et al.  Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients , 2018, Journal of Immunotherapy for Cancer.

[46]  Susan M. Keating,et al.  Opportunities and Challenges in Implementation of Multiparameter Single Cell Analysis Platforms for Clinical Translation , 2018, Clinical and translational science.

[47]  Eddy J. Bautista,et al.  Integrative Personal Omics Profiles during Periods of Weight Gain and Loss. , 2018, Cell systems.

[48]  L. Hood,et al.  The building blocks of successful translation of proteomics to the clinic , 2018, Current opinion in biotechnology.

[49]  R. Trevethan,et al.  Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice , 2017, Front. Public Health.

[50]  Wendy Lipworth,et al.  Use of Real-World Data for the Research, Development, and Evaluation of Oncology Precision Medicines. , 2017, JCO precision oncology.

[51]  A. Emili,et al.  Protein complexes, big data, machine learning and integrative proteomics: lessons learned over a decade of systematic analysis of protein interaction networks , 2017, Expert review of proteomics.

[52]  Brian M Alexander,et al.  Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE , 2017, Clinical Cancer Research.

[53]  L. Staudt,et al.  The NCI Genomic Data Commons as an engine for precision medicine. , 2017, Blood.

[54]  M. Thiagarajan.  Abstract 399: CPTAC phase II final report , 2017 .

[55]  Matthew J. Selleck,et al.  Making Meaningful Clinical Use of Biomarkers , 2017, Biomarker insights.

[56]  David Haussler,et al.  Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions. , 2017, The New England journal of medicine.

[57]  Sharon S. Hori,et al.  A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers. , 2017, Cancer research.

[58]  Michael B. Stadler,et al.  An Immune Atlas of Clear Cell Renal Cell Carcinoma , 2017, Cell.

[59]  I. Tannock,et al.  Limits to Personalized Cancer Medicine. , 2016, The New England journal of medicine.

[60]  C. Lim,et al.  Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment , 2016, Science Advances.

[61]  R. Govindan,et al.  Clinical Implications of Genomic Discoveries in Lung Cancer. , 2016, The New England journal of medicine.

[62]  Yuri A. Mirokhin,et al.  A Description of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Common Data Analysis Pipeline. , 2016, Journal of proteome research.

[63]  H. Grönberg,et al.  Evolving Recommendations on Prostate Cancer Screening. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[64]  Jeffrey R. Whiteaker,et al.  Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. , 2016, Clinical chemistry.

[65]  Birgit Schoeberl,et al.  Beyond static biomarkers—The dynamic response potential of signaling networks as an alternate biomarker? , 2015, Science Signaling.

[66]  Saeed Safari,et al.  Evidence Based Emergency Medicine Part 2: Positive and negative predictive values of diagnostic tests , 2015, Emergency.

[67]  V. Anne Smith,et al.  Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system , 2015 .

[68]  Subha Madhavan,et al.  The CPTAC Data Portal: A Resource for Cancer Proteomics Research. , 2015, Journal of proteome research.

[69]  George Poste,et al.  The national biomarker development alliance: confronting the poor productivity of biomarker research and development , 2015, Expert review of molecular diagnostics.

[70]  Min Wu,et al.  Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor , 2015, Cancer informatics.

[71]  L. Maxim,et al.  Screening tests: a review with examples , 2014, Inhalation toxicology.

[72]  Brendan MacLean,et al.  CPTAC Assay Portal: a repository of targeted proteomic assays , 2014, Nature Methods.

[73]  Helen M Moore,et al.  Moving toward biospecimen harmonization with evidence-based practices. , 2014, Biopreservation and biobanking.

[74]  J. Buhmann,et al.  Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry , 2014, Nature Methods.

[75]  F. Collins,et al.  Policy: NIH plans to enhance reproducibility , 2014, Nature.

[76]  Pei Wang,et al.  Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins , 2013, Nature Methods.

[77]  Helen M. Moore,et al.  National Cancer Institute Biospecimen Evidence-Based Practices: a novel approach to pre-analytical standardization. , 2014, Biopreservation and biobanking.

[78]  C. Compton,et al.  Breaking a Vicious Cycle , 2013, Science Translational Medicine.

[79]  Matthias Mann,et al.  Direct Proteomic Quantification of the Secretome of Activated Immune Cells , 2013, Science.

[80]  G. Omenn,et al.  Evolution of Translational Omics: Lessons Learned and the Path Forward , 2013 .

[81]  Scott E Kern,et al.  Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. , 2012, Cancer research.

[82]  R. Cheong,et al.  How Information Theory Handles Cell Signaling and Uncertainty , 2012, Science.

[83]  Raymond Vanholder,et al.  Implementation of proteomic biomarkers: making it work , 2012, European journal of clinical investigation.

[84]  J. Baron.  Screening for cancer with molecular markers: progress comes with potential problems , 2012, Nature Reviews Cancer.

[85]  John T. Wei,et al.  Beyond PSA: The Next Generation of Prostate Cancer Biomarkers , 2012, Science Translational Medicine.

[86]  Sanjiv S Gambhir,et al.  Mathematical Model Identifies Blood Biomarker–Based Early Cancer Detection Strategies and Limitations , 2011, Science Translational Medicine.

[87]  Daniel Gallahan,et al.  Systems biology: confronting the complexity of cancer. , 2011, Cancer research.

[88]  K. Jayaraman.  13,000-biomarker deal , 2011, Nature Biotechnology.

[89]  S. Hanash,et al.  Impact of Protein Stability, Cellular Localization, and Abundance on Proteomic Detection of Tumor-Derived Proteins in Plasma , 2011, PloS one.

[90]  G. Poste.  Bring on the biomarkers , 2011, Nature.

[91]  Vittorio Cristini,et al.  Multiscale cancer modeling. , 2010, Annual review of biomedical engineering.

[92]  H. Rodriguez,et al.  Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: An NCI‐CPTC initiative perspective , 2010, Proteomics. Clinical applications.

[93]  S. Hanash,et al.  Confounding Effects of Hormone Replacement Therapy in Protein Biomarker Studies , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[94]  E. Diamandis,et al.  Cancer biomarkers: can we turn recent failures into success? , 2010, Journal of the National Cancer Institute.

[95]  J. Manson,et al.  Postmenopausal estrogen and progestin effects on the serum proteome , 2009, Genome Medicine.

[96]  M. Tainsky,et al.  Genomic and proteomic biomarkers for cancer: a multitude of opportunities. , 2009, Biochimica et biophysica acta.

[97]  Christoph H Borchers,et al.  Corrigendum: Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[98]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[99]  E. Diamandis,et al.  Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers*S , 2009, Molecular & Cellular Proteomics.

[100]  Jos H. Beijnen,et al.  Clinical proteomics in breast cancer: a review , 2009, Breast Cancer Research and Treatment.

[101]  Andrew N Hoofnagle,et al.  Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. , 2008, Clinical chemistry.

[102]  Pei Wang,et al.  The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline , 2008, Proteomics. Clinical applications.

[103]  M. Lai,et al.  The cancer secretome: a reservoir of biomarkers , 2008, Journal of Translational Medicine.

[104]  Sanjiv S Gambhir,et al.  Cancer Screening: A Mathematical Model Relating Secreted Blood Biomarker Levels to Tumor Sizes , 2008, PLoS medicine.

[105]  Michel Tod,et al.  Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. , 2008, Clinical biochemistry.

[106]  Michelle A. Anderson,et al.  A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development , 2008, PLoS medicine.

[107]  S. Hanash,et al.  Mining the plasma proteome for cancer biomarkers , 2008, Nature.

[108]  S. Hanash,et al.  Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. , 2008, Journal of proteome research.

[109]  Benno Schwikowski,et al.  Assessing Bias in Experiment Design for Large Scale Mass Spectrometry-based Quantitative Proteomics*S , 2007, Molecular & Cellular Proteomics.

[110]  Clive R Taylor,et al.  Recommendations for Improved Standardization of Immunohistochemistry , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[111]  N. Anderson,et al.  A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.

[112]  E. O’Shea,et al.  Quantification of protein half-lives in the budding yeast proteome , 2006, Proceedings of the National Academy of Sciences.

[113]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[114]  Sang Joon Kim,et al.  A Mathematical Theory of Communication , 2006 .

[115]  D. Ransohoff.  Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.

[116]  P. Bohley.  The fates of proteins in cells , 1995, Naturwissenschaften.

[117]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[118]  J. Potter,et al.  A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. , 2003, Biostatistics.

[119]  David E. Misek,et al.  Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice , 2003, Genome Biology.

[120]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[121]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[122]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[123]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[124]  K. Pienta,et al.  Cancer as a complex adaptive system. , 1996, Medical hypotheses.

[125]  Dale McLerran,et al.  An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. , 1993, JAMA.

[126]  M. W. Pandit,et al.  Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. , 1990, Protein engineering.

[127]  S. Rogers,et al.  Microinjection of ubiquitin: changes in protein degradation in HeLa cells subjected to heat-shock , 1987, The Journal of cell biology.

[128]  W. Mastropaolo,et al.  Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation. , 1986, Clinical chemistry.

[129]  S. Rogers,et al.  Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. , 1986, Science.